XXXX and @entity3085 : the effect of short-term treatment with @entity2816 on weight loss and lean body mass.

@entity1 @entity5 @entity2816 @entity3085 @entity1017
BACKGROUND: @entity3085 is common in @entity1 with advanced @entity5 and has a direct impact on well-being and mortality. AIM: To test the hypothesis that @entity2816 can promote @entity1017 and lean body mass in @entity1 with advanced @entity5 . METHODS: In an open-label study, 11 @entity1 with non-obstructing and inoperable @entity5 were established on an isocaloric diet for 2 weeks, followed by 2 weeks on @entity2816 , 200 mg daily. The primary end-points were weight change and lean body mass. Secondary end-points were quality of life and changes in resting energy expenditure. RESULTS: Ten @entity1 completed the study protocol. The average caloric intake remained the same throughout the study period in all @entity1 . Nine of 10 @entity1 (95% confidence interval, 0.60, 0.98) lost weight on diet alone. The mean @entity1017 on @entity2816 in the following 2 weeks was 1.29 kg (median, 1.25 kg). A similar trend was shown in the lean body mass. Eight of nine @entity1 (95% confidence interval, 0.57, 0.98) initially lost lean body mass on diet alone (missing data in one @entity1 ). The mean gain in lean body mass on @entity2816 in the following 2 weeks was 1.75 kg (median, 1.33 kg). CONCLUSIONS: @entity2816 treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period.
